Genetic Technologies Limited (ADR)  

(Public, NASDAQ:GENE)   Watch this stock  
Find more results for Genetic Technologies Limited�
0.850
-0.010 (-1.14%)
Jul 29 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.82 - 0.88
52 week 0.81 - 3.00
Open 0.84
Vol / Avg. 102,126.00/225,798.00
Mkt cap 13.47M
P/E     -
Div/yield     -
EPS -0.56
Shares 475.47M
Beta 0.57
Inst. own 0%

Key stats and ratios

Q2 (Jun '13) 2013
Net profit margin -192.38% -111.58%
Operating margin -192.38% -111.58%
EBITD margin - -103.85%
Return on average assets -106.03% -75.52%
Return on average equity -135.46% -93.52%
Employees 64 -
CDP Score - -

Address

60-66 Hanover Street, Fitzroy
Fitzroy, VIC 3065
Australia
+61-3-84127000 (Phone)
+61-3-84127040 (Fax)

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Genetic Technologies Limited (GTG) is engaged the provision of genetic testing services. The Company also conducts out-licensing program in respect of its non-coding deoxyribonucleic acid technology and supports a late-stage research project. The Company operates in three segments: Operations, Licensing and Research. The principal geographic segments of the Company include Australia, with the Company�s headquarters being located in Melbourne in the State of Victoria. The Operations segment includes the provision of a range of genetic testing services. The Licensing segment includes the out-licensing of the Group�s non-coding technology. The Research segment includes the undertaking of a range of research and development projects in the field of genetics and related areas. During the fiscal year ended June 30, 2012, the Company launched its new, predictive risk test, BREVAGen. BREVAGen is the clinically validated breast cancer predictive risk assessment tool.

Officers and directors

Eutillio Buccilli Chief Financial Officer
Bio & Compensation  - Reuters
Mark Ostrowski Senior Vice President - Sales & Marketing, Phenogen Sciences Inc
Age: 50
Bio & Compensation  - Reuters
Richard Allman Ph.D Scientific Director
Age: 53
Bio & Compensation  - Reuters
M. Luisa Ashdown Director of Global Licensing and Intellectual Property
Age: 57
Bio & Compensation  - Reuters
Diana Newport Quality and Business Operations Director
Age: 56
Bio & Compensation  - Reuters
Malcolm Roy Brandon Ph.D. Non-Executive Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
Grahame James Leonard Director
Bio & Compensation  - Reuters
Ian Farquhar Campbell McKenzie Ph.D. Director
Bio & Compensation  - Reuters
Mervyn Cass Non-Executive Director
Age: 72
Bio & Compensation  - Reuters
Paul Alexander Kasian Non-Executive Director
Bio & Compensation  - Reuters